Immunome (NASDAQ:IMNM) Director Isaac Barchas Sells 20,840 Shares

Immunome, Inc. (NASDAQ:IMNM) Director Isaac Barchas sold 20,840 shares of the stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $26.06, for a total transaction of $543,090.40. Following the completion of the transaction, the director owned 87,664 shares in the company, valued at $2,284,523.84. This trade represents a 19.21% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Isaac Barchas also recently made the following trade(s):

• On Friday, August 7th, Isaac Barchas sold 15,248 shares of Immunome stock. The stock was sold at an average price of $26.06, for a total value of $397,362.88.
• On Tuesday, July 7th, Isaac Barchas sold 16,906 shares of Immunome stock. The shares were sold at an average price of $24.20, for a total transaction of $409,125.20.
• On Monday, July 6th, Isaac Barchas sold 83,094 shares of Immunome stock. The stock was sold at an average price of $24.11, for a total value of $2,003,396.34.
• On Thursday, July 2nd, Isaac Barchas sold 100,000 shares of Immunome stock. The shares were sold at an average price of $22.59, for a total transaction of $2,259,000.00.
• On Tuesday, June 30th, Isaac Barchas sold 101,050 shares of Immunome stock. The stock was sold at an average price of $21.12, for a total value of $2,134,176.00.

Immunome Stock Performance

NASDAQ:IMNM traded up $0.66 during trading hours on Monday, reaching $25.69. The stock had a trading volume of 1,228,372 shares, compared to its average volume of 1,385,460. Immunome, Inc. has a 52 week low of $8.66 and a 52 week high of $27.65. The stock has a market capitalization of $2.91 billion, a PE ratio of -10.79 and a beta of 2.07. The company has a 50 day moving average price of $21.49 and a two-hundred day moving average price of $22.16.

Immunome (NASDAQ:IMNM) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.48) EPS for the quarter, topping the consensus estimate of ($0.60) by $0.12. Equities research analysts predict that Immunome, Inc. will post -2.06 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on IMNM shares. Truist Financial raised their price objective on Immunome from $36.00 to $37.00 and gave the company a “buy” rating in a research report on Thursday, May 28th. HC Wainwright reissued a “buy” rating on shares of Immunome in a report on Thursday, July 9th. Leerink Partners decreased their price target on Immunome from $37.00 to $33.00 and set an “outperform” rating for the company in a report on Friday, May 15th. Citigroup reaffirmed a “buy” rating on shares of Immunome in a research note on Thursday, July 9th. Finally, Wedbush reiterated an “outperform” rating and issued a $31.00 price objective on shares of Immunome in a report on Tuesday, July 21st. Twelve analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $34.18.

Institutional Investors Weigh In On Immunome

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. BlackRock Inc. purchased a new stake in Immunome in the 2nd quarter valued at approximately $186,588,000. T. Rowe Price Investment Management Inc. raised its stake in Immunome by 59.4% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 13,421,987 shares of the company’s stock worth $288,305,000 after purchasing an additional 5,003,824 shares during the period. JPMorgan Chase & Co. boosted its holdings in shares of Immunome by 8,659.2% in the 4th quarter. JPMorgan Chase & Co. now owns 2,855,747 shares of the company’s stock valued at $61,341,000 after purchasing an additional 2,823,144 shares during the last quarter. Primecap Management Co. CA raised its holdings in Immunome by 55.2% in the fourth quarter. Primecap Management Co. CA now owns 4,685,441 shares of the company’s stock valued at $100,643,000 after buying an additional 1,667,432 shares during the period. Finally, Balyasny Asset Management L.P. acquired a new position in Immunome during the fourth quarter valued at approximately $30,710,000. 44.58% of the stock is currently owned by institutional investors and hedge funds.

About Immunome

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.